Working… Menu

Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00575627
Recruitment Status : Unknown
Verified June 2008 by University of Turin, Italy.
Recruitment status was:  Recruiting
First Posted : December 18, 2007
Last Update Posted : June 4, 2008
Information provided by:
University of Turin, Italy

Brief Summary:
Patients with chronic hepatitis C with persistently normal alanine aminotransferase (ALT) levels have been generally excluded from treatment, because the strong conviction that normal ALT would be synonymous of absence of liver damage. However, recent studies have demonstrated marked liver fibrosis, including cirrhosis, in patients with HCV and persistently normal ALT levels. Up to now, just a sigle randomized, controlled, multicenter study was lead to evaluate the efficacy and safety of combined therapy in patients with chronic hepatitis C and persistently normal serum ALT levels. Aim of our study is evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: Peg-Interferon alpha2a plus Ribavirin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin
Study Start Date : September 2007
Estimated Primary Completion Date : September 2009
Estimated Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: 2
Experimental: 1
Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
Drug: Peg-Interferon alpha2a plus Ribavirin
Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily

Primary Outcome Measures :
  1. To evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients. [ Time Frame: 48-72 weeks ]

Secondary Outcome Measures :
  1. evaluation of liver fibrosis by Fibroscan after 48-72 weeks of inclusion [ Time Frame: 48-72 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Serologic evidence of chronic hepatitis C infection (repeatedly HCV-RNA positive) with persistent normal ALT levels documented on at least 3 occasions, in the last 18 months before screening.
  • Fibroscan performed in the last 3 months
  • Compensated liver disease, Child Pugh score <7
  • Serum HCV-RNA >615 IU/mL
  • Patients who are naïve to any hepatitis C therapy (i.e. have not been previously treated with an interferon or with IFN plus ribavirin)
  • No clinical or radiological evidence of hepatocellular carcinoma and a serum AFP <100 ng/mL within 2 months of randomisation
  • Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
  • All fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding
  • History or other evidence of bleeding from oesophageal varices or other conditions consistent with decompensated liver disease (Child Pugh B or C)
  • Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) £6 months prior to the first dose of study drug
  • History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
  • Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening
  • Serum creatinine level >1.5 times the upper limit of normal at screening
  • Evidence of current severe psychiatric disease, especially depression within one year of study entry. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, within 12 months prior to study entry. Patients with a previous history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease should be evaluated by a qualified Psychiatrist for study suitability prior to enrolment.
  • History of a severe seizure disorder or current anticonvulsant use History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
  • History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
  • Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)
  • Evidence of drug abuse (including excessive alcohol consumption) within 6 months of study entry
  • Inability or unwillingness to provide informed consent or abide by the requirements of the study
  • Male partners of women who are pregnant
  • Hgb <12 g/dL in women or <13 g/dL in men at screening
  • Any patient with an increased baseline risk for anemia (e.g. thalassemia, spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically problematic
  • Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would not be well-tolerated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00575627

Layout table for location contacts
Contact: RIZZETTO Mario, MD +39-011-6336397
Contact: CIANCIO Alessia, MD, PhD +39-011-6336224

Layout table for location information
Università degli Studi di Torino - Azienda Ospedaliera San Giovanni Battista di Torino, Molinette, Recruiting
Torino, Italy, 10126
Contact: Ciancio Alessia, MD, PhD    +39-0116336224   
Principal Investigator: Ciancio Alessia, MD, PhD         
Sponsors and Collaborators
University of Turin, Italy
Layout table for investigator information
Principal Investigator: Rizzetto Mario Università degli Studi di Torino - Azienda Ospedaliera San Giovanni Battista di Torino, Molinette,
Layout table for additonal information
Responsible Party: Prof Mario Rizzetto - Dipartimento di GastroEpatologia - Università degli Studi di Torino, Università degli Studi di Torino Identifier: NCT00575627    
Other Study ID Numbers: pNNALTHCV
First Posted: December 18, 2007    Key Record Dates
Last Update Posted: June 4, 2008
Last Verified: June 2008
Keywords provided by University of Turin, Italy:
Hepatitis C
persistently normal ALT
Theraphy for Hepatitis C
Pegylated Interferon
Combined therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Blood-Borne Infections
Communicable Diseases
Flaviviridae Infections
Interferon alpha-2
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs